PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: MDxHealth, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MDxHealth to Present Results from Epigenetic Prostate Test to Identify Aggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014 - MDxHealth SA announced that the company will present results from an important study involving the development of their prostate cancer (PCa) aggressiveness test at the ASCO Genitourinary Cancers Symposium 2014 in San Francisco, CA
MDxHealth to Present Results from Epigenetic Prostate Test to Identify Aggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014

 

NewswireToday - /newswire/ - Irvine, CA, United States, 2014/01/29 - MDxHealth SA announced that the company will present results from an important study involving the development of their prostate cancer (PCa) aggressiveness test at the ASCO Genitourinary Cancers Symposium 2014 in San Francisco, CA. NYSE Euronext: MDXH

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from an important study involving the development of their prostate cancer (PCa) aggressiveness test at the ASCO Genitourinary Cancers Symposium 2014 in San Francisco, California, USA (January 30 - February 1, 2014).

In current standard medical practice PCa prognosis and aggressiveness are mainly guided by Gleason score (GS), as determined on biopsied tissue. However, due to sampling errors biopsied prostate tissue might not be representative of the actual disease. MDxHealth is currently developing an epigenetic prostate cancer test to identify men with aggressive disease and adverse prognosis.

Details of presentation (time is Pacific Standard Time):

Friday, January 31, 2014

Abstract Title: Epigenetic profiling of prostate cancer tissue identifies men with high risk disease.
Lead Author: Leander Van Neste PhD, Maastricht University, Dept. of Pathology, GROW - School for Oncology and Developmental Biology, Maastricht, The Netherlands
Location: General poster session B: BRD.A1 (abstract 197)
Time: 12:00pm-1:30pm and 5:45pm-7:15pm

About MDxHealth®

MDxHealth (mdxhealth.com) is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDxTM for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Herstal, Belgium.

Contacts:
Mike Sinclair (media) - Halsin Partners
UK: +44(0)20 7318 2955 / Cell: +44(0)79 6802 2075
E: msinclair[.]halsin.com.

Matt Clawson - Allen & Caron, Inc.
US: +1 949-474-4300 - E: matt[.]allencaron.com.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: MDxHealth, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


MDxHealth to Present Results from Epigenetic Prostate Test to Identify Aggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

MDxHealth, Inc. |
Publisher Contact: Dr. Jan Groen - MDxHealth.com 
949-812-6979 / +32 4 364 20 70 info[.]mdxhealth.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From MDxHealth, Inc. / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Telehealth Vendors Expand mHealth Portfolio to Conquer New Growth Opportunities Finds Frost & Sullivan
GE Healthcare Acquires Asymptote for Complete, Digitally-enabled Cryogenic Cold Chain Technology Supporting Safe Manufacture And Delivery Of Cellular
ANVISA Approval for EMCM Facilitates the Progress of Leader Biomedical Operations in Brazil
GE Healthcare Expands Digital Maternal-Infant Care Offerings with Acquisition of Monica Healthcare
Next-generation Natural Materials to Replace Traditional Synthetic Materials in Personal Care Products Finds Frost & Sullivan
Digital Innovation-driven Diagnostic Advances Transform Smart Healthcare Finds Frost & Sullivan
Hospitals’ Outsourcing of Sterile Processing Expand Opportunities for Third Party Service Providers in the US & Western Europe Finds Frost & Sullivan
Emerging Cardiac Therapies Catalysed by Innovative Product and Next-generation Technology Finds Frost & Sullivan
Austrian Centre of Industrial Biotechnology and GE Healthcare Establish A Cell Line Engineering Collaboration
Sequencing Platform Providers Aim to Develop Tests for Infectious Diseases to Expand Market Opportunity Finds Frost & Sullivan
Arcadia Wins Top Honors from Frost & Sullivan for its Next-generation Clinical and Claims Analytics Platform, Arcadia Analytics
Vendors Favour Platform Monitoring as Novel Service Models Disrupt APAC Home Health Monitoring Market Finds Frost & Sullivan
Leader Biomedical and Urogyn Collaborate to Bring Innovative New Procedure Urolastic™ to India
Emergency Service Partners Joins US Acute Care Solutions
Thriving Healthcare Markets in Asia and Latin America Offer Strong Growth Opportunities for Global Players Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)